Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis

Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis

Background: Head-to-head evidence is lacking in comparative risks of high-grade adverse events (AEs) among different systemic treatment options for advanced melanoma.Methods: An up-to-date systematic review and network meta-analysis (NMA) was performed. Randomized controlled trials (RCTs) of patient...

Full description

Bibliographic Details
Main Authors: Ya-fang Huang, Wen-jie Xie, Hai-yu Fan, Juan Du
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitor (ICI)
targeted inhibitor
network meta-analysis
advanced melanoma
high-grade adverse event
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.571135/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.571135/full

Similar Items